AbbVie (ABBV)
(Delayed Data from NYSE)
$173.61 USD
+1.29 (0.75%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $173.95 +0.34 (0.20%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABBV 173.61 +1.29(0.75%)
Will ABBV be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABBV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABBV
Q2 Earnings in Full Swing This week
First Full Week of Q2 Earnings, PCE Out Friday
ABBV: What are Zacks experts saying now?
Zacks Private Portfolio Services
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
Other News for ABBV
Johnson & Johnson: Seriously Undervalued At Peak Pessimism
Options Volatility and Implied Earnings Moves This Week, July 22 – July 26, 2024
Cerevel Therapeutics gains as investors appear more confident on FTC approval for AbbVie
Kamala Harris' potential impact on health care stocks
Earnings week ahead: TSLA, GOOG, IBM, AAL, GM, F, VZ, T, and more